Judge Denies Sanofi-Aventis' Motion to Dismiss
St. Clair, IL: In a victory for plaintiffs, a judge in St. Clair County has denied a motion by Sanofi-Aventis to dismiss or transfer 59 claims against the company regarding its
antibiotic, Ketek. The judge found that Sanofi-Aventis did not show that St. Clair County was an inadequate forum for the cases and refused to dismiss claims from plaintiffs in other states. [
Read More ]
Ketek and the FDA: Medicinal Terrorism?
Washington, DC: There are those who feel that the real threat to the American people isn't terrorism: it's the seemingly endless supply of dangerous prescription drugs that carry approval by the US Food and Drug Administration (FDA).
Ketek is alleged to be one of them, after patients have
died or been
seriously harmed from the antibiotic. [
Read More ]
Ketek and Aventis' Study 3014: Questions still Unanswered
Washington, DC: The antibiotic
Ketek was approved by the FDA more than three years ago, ostensibly to be used for respiratory tract infections. There was no mention of side effects such as
liver damage and/or
liver failure. Since that time, scandals and treachery—mainly involving study 3014--seem to have held no bounds regarding the drug, its manufacturer and the FDA. [
Read More ]
Telithromycin was approved by the European Commission in July 2001 and gained FDA approval April 1 , 2004.
Ketek (telithromycin) has been linked to liver damage in dozens of cases, some of which resulted in liver failure and death. The manufacturer, Sanofi-Aventis, has stopped a marketing plan for the drug. Health authorities are investigating the use of the antibiotic after numerous cases of liver damage and several deaths. 
